MAP3K1-targeting therapeutic artificial miRNA suppresses the growth and invasion of breast cancer in vivo and in vitro
- Chun Liu†1,
- Shengjie Wang†2,
- Shunxing Zhu1,
- Haifeng Wang2,
- Jiayi Gu1,
- Zeping Gui1,
- Jin Jing1,
- Xiaofan Hou1 and
- Yixiang Shao1Email author
© Liu et al. 2016
Received: 4 December 2015
Accepted: 7 December 2015
Published: 4 January 2016
Recent investigations have highlighted that therapeutic artificial microRNAs could be promising candidates for cancer therapy through the modulation of tumor promoter or suppressor. MEK kinase 1 (MEKK1) is expressed by mitogen-activated kinase kinase kinase 1 (MAP3K1), an important kinase that links Ras activation to MAPK signaling. In the present study, we showed that synthetic MAP3K1-targeting artificial miRNA may provide considerable beneficial effects in the prevention of breast cancer growth and metastasis. We showed that MEKK1 was highly expressed in human breast cancer specimens, compared with adjacent normal tissues. Using a miRNA-expressing lentivirus system, we delivered a artificial miRNA (Map3k1 amiRNA) that targets MAP3K1 into 4T1 breast cancer cells and investigated the impact of MAP3K1-targeting miRNA on the growth and invasive behavior of breast cancer in vitro and in vivo. We found that overexpression of Map3k1 amiRNA led to impaired activities of p-ERK and p-p38. In addition, Map3k1 amiRNA induced marked proliferative impairment and invasive attenuation in breast cancer cells. However, Map3k1 amiRNA did not have evident influence on the apoptotic response of 4T1 cells. Moreover, using in vivo nude mice model, we identified that Map3k1 amiRNA attenuated tumor growth and lung metastasis of breast cancer cells. Taken together, our findings explicitly indicated that MEKK1 exerted important oncogenic property in breast cancer development, and MAP3K1-targeting artificial miRNA may provide promising therapeutic effects in the treatment of breast cancer.
KeywordsBreast cancer MAP3K1 Artificial miRNA Tumor growth Metastasis
Breast cancer represents the most frequent cancer among women and a leading cause of cancer-associated mortality around the world. It is estimated that there are annually 1.7 million breast cancer cases worldwide, with 522,000 deaths (Ferlay et al. 2015). Despite the fact that vigorous investigations have been conducted by both basic scientists and clinical researchers, the prognosis of breast cancer remains unfavorable, mainly attributed to late diagnosis and limited therapeutic options (Farazi et al. 2013). In addition, the adverse effects of existing therapies restrict their clinical merits in patients (Cuzick et al. 2011). Currently, a promising strategy of breast cancer therapy is to develop molecular target therapy, which has been proved to exert significant beneficial effects in breast cancer treatment. However, the molecular mechanisms underlying breast cancer development remains not completely understood. Therefore, the clarification of therapeutic targets would benefit the development of novel breast cancer therapies.
Breast tumorigenesis involves complex molecular mechanisms. A variety of important cellular signaling pathways have been critically implicated in the initiation and progression of breast cancer, such as MAPK cascades, Wnt/β-catenin, PI3K/AKT etc. From their discoveries, MAPK signaling has been a focus of cancer investigations, including breast cancer (Wagner and Nebreda 2009). MAPKs are a family of typical serine-threonine kinases and are divided into three major MAPK subfamilies, namely p38, JNK and ERK kinases. MAPKs are typical kinase members that are activated through upstream kinase cascades. MEKK1 was initially identified as a kinase that facilitates the activation of MEK and MAPK kinases (Yan et al. 1994). Later on, it was reported that MEKK1 may phosphoryate IκBα and IκBβ kinase complexes, leading to consequent NF-κB activation (Lee et al. 1998). M Russell reported that MEKK1 interacted directly with Ras, implying that MEKK1 may be a downstream effector of Ras signaling (Russell et al. 1995). Accumulating data have suggested a crucial involvement of MEKK1 in tumor biology. For example, blockage of MEKK1 inhibited the survival, invasion and migration of human pancreatic cancer cells (Hirano et al. 2002; Su et al. 2009). Lysophosphatidic acid promotes ovarian cancer cell migration through Ras-MEKK1 signaling (Bian et al. 2004). Rangaswami H reported that Osteopontin triggered the growth and lung metastasis of melanoma via MEKK1-dependent MMP-9 expression (Rangaswami and Kundu 2007). Interestingly, mammary MEKK1-deficient mice exhibit no difference in tumor initiation. However, the dissemination and metastasis of breast cancer is significantly delayed in MEKK1-deficient mice (Cuevas et al. 2006). These findings conceivably indicate that MEKK1 plays a facilitating role in the development of diverse tumor types. However, the expression pattern and physiological significance of MEKK1 in human breast cancer remains to be elucidated.
Recent investigations have pointed to key roles of microRNAs (miRNAs) in the regulation of cellular signaling and cancer biology (Farazi et al. 2013; Miska 2005). It has been well-established that miRNAs modulates the expression of various signaling transducers through binding to their mRNA 3′-terminal and inducing rapid decay of the mRNAs. As such, the utility of synthetic miRNAs as candidate targeted therapy has been proposed as a promising therapy of human diseases (Garofalo and Croce 2011). Kota J reported that the delivery of synthetic therapeutic miR-26a induces cell-cycle arrest in liver cancer cells through targeting Cyclin D2 and E1. Notably, they uncovered that in vivo systemic administration of miR-26a hindered tumor growth, induced tumor-specific apoptosis and protected mice from hepatocellular carcinoma progression with no cytotoxic effects (Kota et al. 2009). In addition to endogenous miRNA, artificially designed miRNAs that specifically target known oncogenes have attracted significant research attention. Masashi Idogawa reported that combined expression of p53 and artificial p21-targeting miRNA induced apparent apoptosis of colon cancer cells in vivo (Idogawa et al. 2009). The delivery of synthetic miRNAs has reportedly exerted powerful tumor-suppressive effects in many other cancer types, such as gastric cancer, bladder cancer and melanoma (Li et al. 2006; Liu et al. 2012a, b). In breast cancer, it was also found that targeting CXCR4 using artificial miRNA blocked the invasion and metastasis of breast cancer cells (Liang et al. 2007). Artificial miRNA-mediated MTDH knockdown inhibits the proliferation, motility and migration of breast cancer cells (Wang et al. 2012). These findings together suggest that artificially designed miRNA may be a valuable approach in the treatment of breast cancer.
Given the information mentioned above, we analyzed the expression of MEKK1 in human breast cancer specimens, and designed an artificial miRNA to specifically suppress the expression of MEKK1 and investigated the impact of miRNA-mediated MAP3K1 silencing on breast cancer physiology. We found that MEKK1 was highly expressed in breast cancer tissues, compared with adjacent normal ones. Moreover, we revealed that blockage of MEKK1 using artificial Map3k1 amiRNA suppressed the growth, lung metastasis and invasion of breast cancer. Our findings implicated that MAP3K1-targeting miRNA might be of important therapeutic merit in breast cancer management.
Cell lines and transfection
Murine breast carcinoma 4T1 cells and Human breast cancer cell lines, MCF-7 and MDA-MB-231 were purchased from ATCC. The cells were maintained in RPMI-1640 medium (Gibco) supplemented 10 % fetal bovine serum (Hyclone). Cells were grown at 37 ℃ in a humidified incubator with 5 % CO2 atmosphere. Cells were grown at an exponential growth rate and harvested using 0.1 % trypsin–EDTA when cultures are approximately 80 % confluent. Cells were transfected using Lipofectamine 2000 (invitrogen) according to the manufacturer’s instruments.
The design of MAP3K1-targeting amiRNA
MAP3K1 gene silencing was achieved by using a vector-based system to produce artificial miRNA. The amiRNA expression vector (pcDNA™6.2-GW/EmGFP-miR) was a gift from Dr. Sun HuaiChang, yangzhou university. We got the sequence of mice MAP3K1 gene from NCBI database (Accession number:NM_011945.2), with the help of INVITROGEN Block-iT RNAi Designer software, we analysed the MAP3K1 sequence and synthesis five candidate miRNA sequences with the highest star-rating (data not shown). Furthermore, Map3k1 amiRNA sequence was subcloned into the eGFP-GV273 vector and lentivirus was packed using the Lentivector Expression Systems (GENECHEM, Shanghai, China).
Quantitative real time PCR analysis
Total RNA was isolated from breast cancer cells by using Trizol (invitrogen), and cDNA was generated by reverse transcription system kit (invitrogen). Real-time PCR was used to detect relative gene expression using SYBR-Green real-time PCR mixes (Roche). GAPDH was used as the internal control, and the expression difference of MAP3K1 gene between every groups was analyzed by statistical software Graphpad prism 5.
Western blot analysis
Total protein was isolated from breast cancer cells using RIPA buffer containing 1 % PMSF, protein concentration was determined using a BCA protein assay kit (Beyotime, China). Protein samples were run in a 6 % seperating gel, and then transferred onto a nitrocellulose membrane. The membranes were blocked for 2 h at 4 ℃ with Tris-buffered saline-Tween 20 (TBST) containing 5 % skimmed milk, and probed with primary antibodies angainst MEKK1 (Santa Cruz), ERK and P-ERK (Cell signaling technology, CST), JNK and P-JNK (CST), P38 and p-p38 (CST), and internal control GAPDH (Santa Cruz). Antibodies were diluted in TBST containing 5 % skimmed milk. After 12 h incubation at 4 ℃, the membranes were washed in TBST 10 min for three times. Then, the membrane was incubated with Goat Anti-Rabbit IRDye®800CW (ODYSSEY) for 2 h at room temperature. After additional washes, the protein bands were visualized by ODYSSEY System.
Immunofluorescence cell staining
The cells growing on the glass slide were fixed by 4 % paraformaldehyde, washed in PBS for 20 min, and then permeablized in 0.1 % Triton X-100/TBS for 10 min. Thereafter, the cells were blocked using 10 % goat serum for 1 h. After washing, slides were incubated with antibodies to MEKK1(Santa CRUZ, 1:200) overnight at 4 ℃. After washing, the cells were incubated with Cy3-conjugated anti-goat antibodies (Jackson ImmunoResearch) and 4,6-diamidino-2-phenylindole (DAPI) for 2 h. Images were captured using a Zeiss Axiovert microscope. EdU (Ribobio) and TUNEL (Promega) assays were performed according to manufacturers recommendations.
H&E and immunohistochemistry
Mammary and lung tissues were fixed in 4 % paraformaldehyde and embedded in paraffin for sectioning. Next, the sections were subjected to HE staining in accordance with the standard HE protocol. Breast cancer clinical pathologic specimens (provided by AFFINIATED HOSPITAL OF NANTONG NUNIVERSITY) were immunostained with an anti-MEKK1 antibody (Santa Cruz, 1:100). Then, SP immunohistochemical staining kits was used according to manufacturers protocol (ZSGB-BIO).
Migration and invasion assay
Wound-healing experiment was employed to detect the migration ability of 4T1 cells in vitro. 4T1 cells were transfected with Map3k1 amiRNA-3 or contol-amiRNA. When the cells reached 60 % confluence, 1 ml tip was used to scratch about 2 mm region along the plate Central line and the medium was replaced into serum-free medium. The cells were incubated at 37 ℃ for an additional 24 h. The images of cells were capture by Zeiss Axiovert microscope. The number of cells migrated to scratch region were analyzed to compare the migration ability of 4T1cells.
The invasion ability of 4T1 cells was assessed by Transwell (Corning) smeared with Matrigel (BD) assay. 4T1 cells transfected with Map3k1 amiRNA-3 or contol amiRNA were cultivated in serum-free medium, wherein 5 × 105 cells were planted to invade through a filter (8 μm) toward 5 % serum-containing medium for 24 h. Thereafter, the invading cells were stained with Wright’s stian and counted for comparing the invasion ability of 4T1 cells.
Colony formation assay
A suspension of 4T1 cells (5 × 103 cells) was prepared in 0.35 % agar, which were added to a 6 cm plate over a base agar layer (0.6 %). Overlayed agar changed once a week, plates were incubated at 37 ℃ in a humidified incubator for 2 weeks. At termination, the colonies were stained with Crystal Violet and counted on a dissecting microscope. Positive colonies were defined as clusters consisting of more than 50 cells.
Tumorigenesis and lung metastasis model
BALB/c-nude mice were employed to analyze the ability of tumorigenesis and lung metastasis of 4T1 cells in vivo. For assessing tumor incidence and growth, 4T1 cells (1.5 × 106 cells/mice) infected with control-amiRNA or Map3k1 amiRNA-3 lentivirus were injected into cleared fat pads of BALB/c-nude mice. Mice were examined for palpable tumors every 2 days, and the growth of the primary tumors was measured once a week using a vernier caliper. Two perpendicular diameters, termed length (L) and width (W), were determined, with length defined as the larger of the two measurements. Volume was calculated using the formula: 1/2 × l × W2, Mice were euthanized 4 weeks after injection of 4T1 cells. Primary tumors were removed and weighed. H&E staining was performed to determine the pathological structure of primary tumors.
To assess the impact of MAP3K1-targeting miRNA on the metastasis of breast cancer, 4T1 cells (5.0 × 105 cells/mice) infected with control-amiRNA or Map3k1 amiRNA-3 lentivirus were transplanted into mice by tail vein injection. The weight of mice was measured once a week. Mice were euthanized 4 weeks after injection of 4T1 cells. Metastasis was evaluated in lungs, which is typical for this tumor due to their visibility and ease of quantification. Lungs were fixed in Bouin’s solution, and metastases were quantified by counting on a dissecting microscope. Finally, H&E staining was performed to analyze the pathological structure of lung metastasis of breast cancer.
Data were analyzed using Prism software (GraphPad Software, Inc., La Jolla, CA). Values were compared using a student’s t test, and a two-sided p value of ≤0.05 was considered significant, and ≤0.01 means very significant.
MEKK1 was highly expressed in human breast cancer specimens
Overexpression of Map3k1 amiRNA down-regulated ERK signaling in breast cancer cells
Map3k1 amiRNA attenuated the proliferation of 4T1 breast cancer cells
Overexpression of Map3k1 amiRNA inhibited the migration and invasion of breast cancer cells
Overexpression of Map3k1 amiRNA did not affect the apoptotic response of breast cancer cells
Overexpression of Map3k1 amiRNA alters the growth and metastasis of breast cancer cells in vivo
The effect of MEKK1 suppression on tumorigenic capacity of 4T1 cells
Incidence of tumorigenesis
Tumor weight (g)
Tumor size (cm3)
5.41 ± 1.39
3.26 ± 0.85
3.09 ± 0.54*
2.35 ± 0.25*
The effect of MEKK1 suppression on metastatic capacity of 4T1 cells
Incidence of metastasis
17 ± 9
8 ± 5*
The MAPK cascades are central signaling pathways that play fundamental roles in many aspects of cellular processes, including proliferation, differentiation, migration and apoptosis. In the present study, we investigated the role and potential therapeutic value of MEKK1 in breast cancer. We found that MEKK1 was upregulated in a majority of breast cancer samples. Of great importance, we showed that miRNA-based MAP3K1 targeting significantly suppressed the proliferation and invasion of breast cancer cells. Additionally, using nude mice, we identified that Map3k1 amiRNA treatment attenuated the progression and lung metastasis of breast cancer in vivo. These data undoubtedly supported the notion that MEKK1 plays an important role in the regulation of breast cancer growth and metastasis, highlighting that miRNA-targeted MAP3K1 depletion is a valuable approach in the treatment of breast cancer.
In recent years, the development of targeted therapy is a most attractive strategy of cancer therapy. In this regard, RNA-based modulation of mRNA and protein expression has attracted significant research attention (Tong et al. 2005). RNA interference has been widely regarded as a promising approach to achieve the goal of protein expression modulation (Devi 2006). However, due to their transient expression and limited delivery system in vivo, the therapeutic efficiencies of RNAi oligos remain unsatisfactory (Zhao et al. 2009). In addition, the use of RNA polymerase III as transcription machinery is difficult to control their expression in desired targeting tissues and cells. miRNAs, a class of polymerase II-directed endogenous small single-stranded RNAs (ssRNA) that share similar acting mechanism with RNAi, may avoid the limitations. It was recently reported that modified shRNA construct using miRNA-based processing machinery may offer more reliable and profound outcome of gene therapy with few side effects in vivo (Stegmeier et al. 2005; McBride et al. 2008). In the current study, we examined whether a similar system may provide favorable result in breast cancer treatment. We found that Map3k1 amiRNA conferred marked tumor-suppressive and anti-metastatic effects through stable MEKK1 depletion in vitro and in vivo. These findings explicitly infer that artificial miRNA may provide considerable therapeutic merit in cancer management.
The oncogenic property of MEKK1 was largely attributed to the activations of downstream MAPK kinases. MAPK kinases play complicated roles in the development of human cancers. For example, ERK MAPKs are activated by a wide range of mitogens and play a predominant role in promoting the growth and metastasis of cancer, including breast cancer (Samatar and Poulikakos 2014). Studies have established that ERK was responsible for enhanced proliferation and migration of breast cancer under many conditions. Bianchi-Smiraglia A et al. reported that integrin β5 contributed to malignant proliferation, tumor angiogenesis and metastasis of breast cancer through the activation of Src-FAK and MEK-ERK signaling pathways (Bianchi-Smiraglia et al. 2013). Discoidin domain receptor 2 (DDR2) facilitates the metastasis of breast cancer through ERK-mediated Snail1 phosphorylation (Zhang et al. 2013). Studies have shown that ERK conferred the proliferation of breast cancer cells through phosphorylation-dependent downregulation and nuclear export of p27 (Foster et al. 2003). In addition to Snail and p27, approximate 160 substrates of ERK kinase have been identified, many of which are critically involved in breast cancer growth and metastasis, such as c-myc, Elk-1 and MSK (Yoon and Seger 2006). These findings implicated an important role of ERK signaling in breast cancer progression and invasion. Coinciding with the notion, our results identified that amiRNA-mediated MAP3K1 silencing could significantly influence ERK pathway, partially accounting for the impaired tumor growth and metastasis. In addition to ERK, our findings suggested that p38 MAPK, to a less extent, was also affected by Map3k1 amiRNA. It is noteworthy that p38 also contributes to the proliferation and metastasis of breast cancer, and inhibition of p38 leads to impaired proliferation of ER-negative breast cancer cells (Chen et al. 2009; Kim et al. 2003). However, some other studies implicated that p38 activation resulted in growth impairment of breast cancer (Cocolakis et al. 2001; Yu et al. 2007). Thus, it remains unclear about the detailed role of p38 in breast cancer physiology following Map3k1 amiRNA overexpression. By contrast, JNK signaling is frequently related with apoptotic response in cancer cells under stress conditions. Our study found that JNK activity was largely unchanged after MEKK1 inactivation, which was consistent with comparable apoptosis between control and Map3k1 amiRNA-overexpressing cells. Notably, as mentioned in introduction section, MEKK1 also played an important role in the regulation of NF-κB signaling, and it is worthy to examine whether NF-κB signaling was altered in our experimental settings, because of the central role of NF-κB signaling in facilitating the metastasis and growth of breast cancer (Huber et al. 2004; Biswas et al. 2004). Taken these information into account, we speculated that Map3k1 amiRNA may decrease the growth and metastasis of breast cancer cells through the regulation of multiple signaling pathways.
Taken all the experimental data in vitro and in vivo, we for the first time reported that MEKK1 was significantly upregulated in breast cancer specimens. Moreover, our findings supported that synthetic artificial miRNA that targets MAP3K1 exert remarkable growth-inhibitory and anti-metastatic effects in breast cancer cells, highlighting that artificial miRNA may confer significant anti-tumor activity through modulating the expression of oncoproteins.
YS managed the project and coordinated the work. CL and SW carried out the molecular and pathological studies, wrote and revised the manuscript. SW, SZ, HW designed and constructed a MAP3K1-targeting artificial miRNA expressing system, and performed the statistical analysis. JG and ZG carried out the cytological studies. CL, JJ, XH participated in establishing the nude mouse animal model of breast cancer, and carried out related animal experiments. All authors read and approved the final manuscript.
The study was supported by Natural Science Foundation of the Jiangsu Higher Education Institutions (No. 14KJB180016), Doctoral scientific research foundation of Nantong University (No. 14B33), Natural science foundation of Nantong University (No. 14ZY016) and College student’s innovation training program of Nantong University (No. 2015094). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Bian D, Su S, Mahanivong C, Cheng RK, Han Q, Pan ZK et al (2004) Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway. Cancer Res 64(12):4209–4217View ArticleGoogle Scholar
- Bianchi-Smiraglia A, Paesante S, Bakin AV (2013) Integrin beta5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways. Oncogene 32(25):3049–3058View ArticleGoogle Scholar
- Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB et al (2004) NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101(27):10137–10142View ArticleGoogle Scholar
- Chen L, Mayer JA, Krisko TI, Speers CW, Wang T, Hilsenbeck SG et al (2009) Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res 69(23):8853–8861View ArticleGoogle Scholar
- Cocolakis E, Lemay S, Ali S, Lebrun JJ (2001) The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin. J Biol Chem 276(21):18430–18436View ArticleGoogle Scholar
- Cuevas BD, Winter-Vann AM, Johnson NL, Johnson GL (2006) MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer. Oncogene 25(36):4998–5010View ArticleGoogle Scholar
- Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B et al (2011) Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 12(5):496–503. doi:https://doi.org/10.1016/S1470-2045(11)70030-4 View ArticleGoogle Scholar
- Devi GR (2006) siRNA-based approaches in cancer therapy. Cancer Gene Ther 13(9):819–829View ArticleGoogle Scholar
- Farazi TA, Hoell JI, Morozov P, Tuschl T (2013) MicroRNAs in human cancer. Adv Exp Med Biol 774:1–20. doi:https://doi.org/10.1007/978-94-007-5590-1_1 View ArticleGoogle Scholar
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. doi:https://doi.org/10.1002/ijc.29210 View ArticleGoogle Scholar
- Foster JS, Fernando RI, Ishida N, Nakayama KI, Wimalasena J (2003) Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway. J Biol Chem 278(42):41355–41366View ArticleGoogle Scholar
- Garofalo M, Croce CM (2011) microRNAs: master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol 51:25–43. doi:https://doi.org/10.1146/annurev-pharmtox-010510-100517 View ArticleGoogle Scholar
- Gomes LR, Terra LF, Wailemann RA, Labriola L, Sogayar MC (2012) TGF-beta1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. BMC Cancer 12:26View ArticleGoogle Scholar
- Hirano T, Shino Y, Saito T, Komoda F, Okutomi Y, Takeda A et al (2002) Dominant negative MEKK1 inhibits survival of pancreatic cancer cells. Oncogene 21(38):5923–5928. doi:https://doi.org/10.1038/sj.onc.1205643 View ArticleGoogle Scholar
- Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H et al (2004) NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 114(4):569–581View ArticleGoogle Scholar
- Idogawa M, Sasaki Y, Suzuki H, Mita H, Imai K, Shinomura Y et al (2009) A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells. Clin Cancer Res 15(11):3725–3732View ArticleGoogle Scholar
- Kim MS, Lee EJ, Kim HR, Moon A (2003) p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res 63(17):5454–5461Google Scholar
- Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, Hwang HW et al (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137(6):1005–1017View ArticleGoogle Scholar
- Lee FS, Peters RT, Dang LC, Maniatis T (1998) MEKK1 activates both IkappaB kinase alpha and IkappaB kinase beta. Proc Natl Acad Sci USA 95(16):9319–9324View ArticleGoogle Scholar
- Li Z, Zhan W, Wang Z, Zhu B, He Y, Peng J et al (2006) Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis. Biochem Biophys Res Commun 348(1):229–237View ArticleGoogle Scholar
- Liang Z, Wu H, Reddy S, Zhu A, Wang S, Blevins D et al (2007) Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem Biophys Res Commun 363(3):542–546View ArticleGoogle Scholar
- Liu Y, Han Y, Zhang H, Nie L, Jiang Z, Fa P et al (2012a) Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells. PLoS One 7(12):e52280View ArticleGoogle Scholar
- Liu X, Fang H, Chen H, Jiang X, Fang D, Wang Y et al (2012b) An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation. PLoS One 7(6):e38659View ArticleGoogle Scholar
- McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I et al (2008) Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 105(15):5868–5873View ArticleGoogle Scholar
- Miska EA (2005) How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 15(5):563–568View ArticleGoogle Scholar
- Rangaswami H, Kundu GC (2007) Osteopontin stimulates melanoma growth and lung metastasis through NIK/MEKK1-dependent MMP-9 activation pathways. Oncol Rep 18(4):909–915Google Scholar
- Russell M, Lange-Carter CA, Johnson GL (1995) Direct interaction between Ras and the kinase domain of mitogen-activated protein kinase kinase kinase (MEKK1). J Biol Chem 270(20):11757–11760View ArticleGoogle Scholar
- Samatar AA, Poulikakos PI (2014) Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov 13(12):928–942View ArticleGoogle Scholar
- Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ (2005) A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci USA 102(37):13212–13217View ArticleGoogle Scholar
- Su F, Li H, Yan C, Jia B, Zhang Y, Chen X (2009) Depleting MEKK1 expression inhibits the ability of invasion and migration of human pancreatic cancer cells. J Cancer Res Clin Oncol 135(12):1655–1663View ArticleGoogle Scholar
- Tong AW, Zhang YA, Nemunaitis J (2005) Small interfering RNA for experimental cancer therapy. Curr Opin Mol Ther 7(2):114–124Google Scholar
- Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9(8):537–549. doi:https://doi.org/10.1038/nrc2694 View ArticleGoogle Scholar
- Wang S, Shu JZ, Cai Y, Bao Z, Liang QM (2012) Establishment and characterization of MTDH knockdown by artificial MicroRNA interference - functions as a potential tumor suppressor in breast cancer. Asian Pac J Cancer Prev 13(6):2813–2818View ArticleGoogle Scholar
- Yan M, Dai T, Deak JC, Kyriakis JM, Zon LI, Woodgett JR et al (1994) Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. Nature 372(6508):798–800View ArticleGoogle Scholar
- Yoon S, Seger R (2006) The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24(1):21–44View ArticleGoogle Scholar
- Yu E, Ahn YS, Jang SJ, Kim MJ, Yoon HS, Gong G et al (2007) Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers. Breast Cancer Res Treat 101(3):269–278View ArticleGoogle Scholar
- Zhang K, Corsa CA, Ponik SM, Prior JL, Piwnica-Worms D, Eliceiri KW et al (2013) The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis. Nat Cell Biol 15(6):677–687View ArticleGoogle Scholar
- Zhao X, Pan F, Holt CM, Lewis AL, Lu JR (2009) Controlled delivery of antisense oligonucleotides: a brief review of current strategies. Expert Opin Drug Deliv 6(7):673–686View ArticleGoogle Scholar